Drugs / PF-06273340
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02260947 | Oct → Dec 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01934738 | Oct 2013 → Mar 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01706796 | Nov 2012 → Jan 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01601834 | May → Jun 2012 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06273340 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01934738 ↗ |
| Action | Inhibit | “PF-06273340 is a small molecule inhibitor of Trks A, B and C” PMID 29178434 ↗ Nov 2017 |
| Modality | Small molecule | “PF-06273340 is a small molecule inhibitor of Trks A, B and C” PMID 29178434 ↗ Nov 2017 |
| Route | Oral | “single oral doses of PF-06273340” NCT01601834 ↗ |